The 2016 revision of the World Health Organization (WHO) classification of tumors of the central nervous system (CNS) had placed major emphasis on the isocitrate dehydrogenase (IDH) mutation status when classifying diffuse gliomas in adults [29]. This evidence concerns the gene IDH1 and central nervous system cancer.